Coya Therapeutics, Inc

Headquartered in Houston, TX, Coya Therapeutics, Inc. (Nasdaq: COYA) is a clinical-stage biotechnology company developing proprietary treatments focused on the biology and potential therapeutic advantages of regulatory T cells (Tregs) to target systemic inflammation and neuroinflammation. Dysfunctional Tregs underlie numerous conditions including neurodegenerative, metabolic, and autoimmune diseases, and this cellular dysfunction may lead to a sustained inflammation and oxidative stress resulting in lack of homeostasis of the immune system. Coyas product candidate pipeline leverages multiple therapeutic modalities aimed at restoring the anti-inflammatory and immunomodulatory functions of Tregs. Coyas therapeutic platforms include Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy....

Coya therapeutics, inc operates in the Biotechnology research industry.

Coya therapeutics, inc's revenue is 1m - 10m

Coya therapeutics, inc has 11 - 50 employees.